Eli Lilly's Obesity Drug Zepbound Hits U.S. Pharmacies with Significant Market Potential
Details:
$Eli Lilly and Co (LLY.US)$ 's new obesity drug Zepbound now available in U.S. pharmacies, priced at $550 a month without insurance coverage.
Zepbound enters a rapidly growing weight-loss drug market, projected to reach $100 billion by decade's end.
Analysts forecast Zepbound sales at about $2 billion in 2024, while Novo Nordisk's Wegovy expected to hit $7.5 billion.
Both Zepbound and Wegovy are GLP-1 agonists, initially for diabetes, showing significant weight reduction effects.
$Pfizer (PFE.US)$ recently halted its obesity drug danuglipron's trials due to side effects.
Zepbound trial results show a 20% average weight reduction, surpassing Wegovy's 15%.
Major PBM Cigna's Express Scripts added Zepbound to its preferred medicines list, with more PBMs reviewing.
Lilly's commercial savings program offers Zepbound as low as $25 with insurance or $550 without.
Eli Lilly's shares surged 60% this year, boosted by Zepbound's market entry.
$Eli Lilly and Co (LLY.US)$ 's new obesity drug Zepbound now available in U.S. pharmacies, priced at $550 a month without insurance coverage.
Zepbound enters a rapidly growing weight-loss drug market, projected to reach $100 billion by decade's end.
Analysts forecast Zepbound sales at about $2 billion in 2024, while Novo Nordisk's Wegovy expected to hit $7.5 billion.
Both Zepbound and Wegovy are GLP-1 agonists, initially for diabetes, showing significant weight reduction effects.
$Pfizer (PFE.US)$ recently halted its obesity drug danuglipron's trials due to side effects.
Zepbound trial results show a 20% average weight reduction, surpassing Wegovy's 15%.
Major PBM Cigna's Express Scripts added Zepbound to its preferred medicines list, with more PBMs reviewing.
Lilly's commercial savings program offers Zepbound as low as $25 with insurance or $550 without.
Eli Lilly's shares surged 60% this year, boosted by Zepbound's market entry.
Why This Matters:
Zepbound's market entry is crucial for stock traders and analysts, given its potential to capture a significant share in a rapidly expanding industry.
The drug's performance and pricing strategy will be key factors in Lilly's financial outlook and the broader pharmaceutical market.
Competition with other obesity treatments, like Novo Nordisk's Wegovy, is expected to intensify, impacting market dynamics.
Zepbound's market entry is crucial for stock traders and analysts, given its potential to capture a significant share in a rapidly expanding industry.
The drug's performance and pricing strategy will be key factors in Lilly's financial outlook and the broader pharmaceutical market.
Competition with other obesity treatments, like Novo Nordisk's Wegovy, is expected to intensify, impacting market dynamics.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
まみおん : It is difficult for most Japanese people to continue taking GLP-1 agonists due to nausea or loss of appetite. Rather, SGLT-2 inhibitors are more common. This removes senescent cells from vascular endothelial cells, leading to anti-aging. However, when used in combination with DDP-4 inhibitors, appetite enhancement can also be prevented.